Moreover, as TGCT is caused by an upregulation of the CSF1 gene and the recruitment of CSF1R-dependent inflammatory cells, tyrosine kinase inhibitors targeting the CSF1 receptor have been used to treat TGCT when surgery is not an option [49]. This evidence concerns the gene CSF1 and tenosynovial giant cell tumor, diffuse type.